BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Etrolizumab: Phase II data

Roche disclosed in its 2012 earnings that the Phase II EUCALYPTUS trial in 120 patients with UC showed that etrolizumab plus immunosuppressant therapy met the primary endpoint of clinical...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >